SCHEMBL5455935

SCHEMBL5455935

Cc1cc(C)cc(Nc2ncnc3ccsc23)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.62
FADS1 O60427 1/20 0.62
PIP4K2C Q8TBX8 1/20 0.60
SYK P43405 1/20 0.60
FLT1 P17948 1/20 0.56
AURKB Q96GD4 2/20 0.50
AURKA O14965 1/20 0.50
PDE4A P27815 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
PDE3B Q13370 1/20 0.48
PDE3A Q14432 1/20 0.48
TEK Q02763 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
BRAF P15056 1/20 0.46
TNNI3K Q59H18 1/20 0.46
NTRK1 P04629 6/20 0.45
AXL P30530 1/20 0.45
MKNK1 Q9BUB5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369046 0.83 EGFR (0.60) EGFRFADS1PIP4K2CSYKFLT1
SCHEMBL5314379 0.82 EGFR (0.56) EGFRFADS1PIP4K2CSYKFLT1
Hydrochloric Acid SCHEMBL5472957 0.81 EGFR (0.56) EGFRFADS1PIP4K2CSYKFLT1
SCHEMBL30715841 0.81 EGFR (0.69) EGFRFADS1PIP4K2CFLT1AURKB
SCHEMBL5372859 0.80 PIP4K2C (0.79) EGFRFADS1PIP4K2CSYKFLT1
SCHEMBL5313058 0.80 EGFR (0.66) EGFRFADS1PIP4K2C
SCHEMBL21542003 0.80 KDR (0.54) EGFRFADS1PIP4K2CSYKFLT1
SCHEMBL24466943 0.79 PIP4K2C (0.62) EGFRFADS1PIP4K2CFLT1AURKB
Hydrochloric Acid SCHEMBL5463170 0.79 EGFR (0.65) EGFRFADS1PIP4K2C
SCHEMBL24466922 0.79 EGFR (0.56) EGFRFADS1PIP4K2CSYKFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US claimed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, API5 EGFR 1226/4885FADS1 1782/4885PIP4K2C 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.